P/B
7,3
Anixa Biosciences
Anixa Biosciences Inc a cancer-focused biotechnology company, develops vaccines and therapies that are focused on critical unmet needs in oncology. The company is developing both diagnostics and therapeutics to detect cancer early, which is curable, and to treat those afflicted once diagnosed. Its segment includes CAR-T Therapeutics; Cancer Vaccines; Anti-Viral Therapeutics and others.
Anixa Biosciences Inc a cancer-focused biotechnology company, develops vaccines and therapies that are focused on critical unmet needs in oncology. The company is developing both diagnostics and therapeutics to detect cancer early, which is curable, and to treat those afflicted once diagnosed. Its segment includes CAR-T Therapeutics; Cancer Vaccines; Anti-Viral Therapeutics and others.
$105.3M
Market Cap • 11/5/2026
1982
(44 years)
Founded
1983
(43 years ago)
IPO
NASDAQ
Listing Exchange
United States
Country
Valuation
P/S
—
P/EBITDA
—
P/OCF
—
P/FCF
—
P/E
—
BVPS
0,4
EPS
—
Market Cap
Market Cap
105,3M
EV
91,6M
EV/Revenue
0
EV/EBITDA
-8,4
EV/EBIT
-8,3
Payout
Dividend Per Share
0
Dividend Yield
0%
Buyback Yield
-5%
Total Yield
-5%
Payout
0%
Retained Earnings
-259,4M
Profitability
Gross Margin
—
EBITDA Margin
—
EBIT Margin
—
Net Margin
—
D&A/EBITDA
0%
R&D/Revenue
0%
Capex/Revenue
0%
Capex/D&A
0%
Capex/OCF
0%
SBC/OCF
—
% PPE
1,1%
% Goodwill
0%
ROE
—
ROIC
—
Growth
CAGR Revenue 5Y
-100%
CAGR Op. Income 5Y
-0,6%
CAGR Net Income 5Y
-1,5%
CAGR EPS 5Y
-4,4%
CAGR OCF 5Y
6,8%
Leverage
N.D./EBITDA
1,3
Debt/Equity
0%
Current Ratio
8,5
Quick Ratio
7,9
Interest Coverage
—
Premium
- Unrestricted access
- Unlimited data history
- Analysis videos
- Quarterly highlights
- Customizable financials table
- Ranking
- Discussions
...and much more!